NewAmsterdam Pharma Retained Earnings vs. EBITDA

NAMSW Stock   7.41  1.26  14.53%   
Based on the key profitability measurements obtained from NewAmsterdam Pharma's financial statements, NewAmsterdam Pharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess NewAmsterdam Pharma's ability to earn profits and add value for shareholders.
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-317 M
Current Value
-301.1 M
Quarterly Volatility
106.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, NewAmsterdam Pharma's Price To Sales Ratio is fairly stable compared to the past year. EV To Sales is likely to climb to 40.30 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 1.61 in 2024. At this time, NewAmsterdam Pharma's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to climb to about 11.8 M in 2024, despite the fact that Operating Income is likely to grow to (157.4 M).
For NewAmsterdam Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NewAmsterdam Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NewAmsterdam Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NewAmsterdam Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NewAmsterdam Pharma over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewAmsterdam Pharma. If investors know NewAmsterdam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.373
Quarterly Revenue Growth
8.898
Return On Assets
(0.29)
Return On Equity
(0.47)
The market value of NewAmsterdam Pharma is measured differently than its book value, which is the value of NewAmsterdam that is recorded on the company's balance sheet. Investors also form their own opinion of NewAmsterdam Pharma's value that differs from its market value or its book value, called intrinsic value, which is NewAmsterdam Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewAmsterdam Pharma's market value can be influenced by many factors that don't directly affect NewAmsterdam Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewAmsterdam Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewAmsterdam Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

NewAmsterdam Pharma EBITDA vs. Retained Earnings Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth.
NewAmsterdam Pharma is rated below average in retained earnings category among its peers. It also is rated below average in ebitda category among its peers . NewAmsterdam Pharma reported Retained Earnings of (316.97 Million) in 2023. Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

NewAmsterdam EBITDA vs. Retained Earnings

Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

NewAmsterdam Pharma

Retained Earnings

 = 

Beginning RE + Income

-

Dividends

 = 
(316.97 M)
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

NewAmsterdam Pharma

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(176.86 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

NewAmsterdam EBITDA Comparison

NewAmsterdam Pharma is currently under evaluation in ebitda category among its peers.

NewAmsterdam Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in NewAmsterdam Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NewAmsterdam Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NewAmsterdam Pharma's change in net profit over the period of time. It can combine multiple indicators of NewAmsterdam Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income4.4 M3.6 M
Net Interest Income3.4 M3.6 M
Interest Income11.3 M11.8 M
Operating Income-165.7 M-157.4 M
Net Loss-176.9 M-168.1 M
Income Before Tax-160.2 M-152.2 M
Total Other Income Expense Net5.5 M5.8 M
Net Loss-160.3 M-152.3 M
Income Tax Expense27 K25.6 K
Net Loss(2.15)(2.26)
Income Quality 0.88  0.74 
Net Income Per E B T 0.99  0.88 

NewAmsterdam Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on NewAmsterdam Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NewAmsterdam Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NewAmsterdam Pharma's important profitability drivers and their relationship over time.

Use NewAmsterdam Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NewAmsterdam Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NewAmsterdam Pharma will appreciate offsetting losses from the drop in the long position's value.

NewAmsterdam Pharma Pair Trading

NewAmsterdam Pharma Pair Trading Analysis

The ability to find closely correlated positions to NewAmsterdam Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NewAmsterdam Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NewAmsterdam Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NewAmsterdam Pharma to buy it.
The correlation of NewAmsterdam Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NewAmsterdam Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NewAmsterdam Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NewAmsterdam Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your NewAmsterdam Pharma position

In addition to having NewAmsterdam Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run ESG Investing Thematic Idea Now

ESG Investing
ESG Investing Theme
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.